Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 05, 2021

            Details:

            The manufacture of the COVID-19 vaccine, AZD1222, will be undertaken by Daiichi Sankyo Biotech Company, at a facility dedicated to the Ministry of Health, Labour and Welfare’s “project to establish a system for developing and producing novel influenza virus vaccines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Isavuconazonium Sulfate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Basilea Pharmaceutica

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2021

            Details:

            The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2020

            Details:

            The Japanese Health Ministry said on Monday its medical review board concluded that clinical trial data to determine the efficacy of Fujifilm Holdings Corp’s COVID-19 drug candidate Avigan is inconclusive.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2020

            Details:

            The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Delamanid

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 25, 2020

            Details:

            Deltyba has potent bactericidal activity against Mycobacterium tuberculosis and is the first approved compound from the bicyclic nitro-imidazole derivatives for the treatment of pulmonary MDR-TB in adult patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Influenza HA Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Kitasato Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: $3.5 million

            Deal Type: Agreement March 27, 2020

            Details:

            After a review of sales strategy and discussions, the companies have reached an agreement to terminate the cooperative sales agreement for Influenza HA Vaccine.